Tocilizumab for Severe and Critical COVID-19 Pneumonia in Queens, NYC

Conclusions Tocilizumab failed to show short-term benefits in clinical outcomes in patients with hypoxic COVID pneumonia at our institution.
Source: Infectious Diseases in Clinical Practice - Category: Infectious Diseases Tags: Original Articles Source Type: research